This site is intended for Healthcare Professionals outside the US

Rapid and significant symptom improvement with JAKAVI

Significant improvement in Total Symptom Score with JAKAVI compared with placebo1

COMFORT-I: Patients with >50% improvements in TSS with JAKAVI vs placebo at Week 241

Significant improvement in Total Symptom Score with JAKAVI, a JAK2 Inhibitor, compared with placebo

Adapted from: Verstovsek S et al. N Engl J Med. 2012;366:799-807.1
A 50% improvement is clinically relevant.

  • Patients treated with JAKAVI had a 46.1% mean improvement in TSS, while patients treated with placebo had a 41.8% mean worsening of score (P<0.001)1

Patients treated with JAKAVI had improvement in individual symptoms compared with placebo and with BAT1,2

COMFORT-I: Improvement from baseline in MFSAF score with JAKAVI vs placebo at Week 241

Patients treated with JAKAVI, a JAK2 inhibitor, had improvement in individual symptoms in COMFORT-I study

Adapted from: Verstovsek S et al. N Engl J Med. 2012;366:799-807.1
Based on a post hoc analysis. Number of patients varied per symptom score; JAKAVI: n=98 to 124, placebo: n=77 to 100.

COMFORT-II: Improvement from baseline in EORTC QLQ-C30 symptom score with JAKAVI vs BAT at Week 482

Patients treated with JAKAVI, a JAK2 inhibitor, had improvement in individual symptoms in COMFORT-II study

Adapted from: Harrison C et al. N Engl J Med. 2012;366:787-798.2
Based on prespecified exploratory analyses. JAKAVI (n=146) and BAT (n=73).

JAKAVI Treatment in Clinical Practice: Addressing previously unrecognized symptom burden

Myelofibrosis symptoms are frequent and severe; however, symptoms also can develop gradually over time and so may not be fully appreciated by patients. Watch the video below to learn more from Dr Ruben Mesa about the importance of discussing potential symptoms with patients in order to effectively manage disease and restore quality of life.

Next: Durable improvement in QoL with JAKAVI treatment

BAT=best available therapy; COMFORT=Controlled Myelofibrosis Study with Oral JAK Inhibitor Treatment; EORTC QLQ-C30=European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire; MFSAF=Myelofibrosis Symptom Assessment Form; QoL=quality of life; TSS=total symptom score.

References:

  1. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799-807.
  2. Harrison C, Kiladjian J-J, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787-798.